Skip to main content
Top
Published in: Arthritis Research & Therapy 4/2009

01-08-2009 | Letter

How much sleep apnea is too much?

Authors: Denis Martinez, Cristiane Maria Cassol, Laura Rahmeier

Published in: Arthritis Research & Therapy | Issue 4/2009

Login to get access

Excerpt

Events of breathing interruption are universally observed during sleep. Togo and colleagues [1], in a study to identify respiratory and movement sleep disorders in chronic fatigue syndrome (CFS) patients with and without fibromyalgia (FM), employed an apnea-hypopnea index (AHI) of 18 events per hour as the normal limit and reported an absence of diagnosable sleep-disordered breathing (SDB). They utilized 18 events per hour as being a threshold 'sufficient to account for excessive daytime sleepiness' and did not report the observed AHI. An institutional task force established five events per hour as the normal AHI limit, based on an ample literature review. The Wisconsin Sleep Cohort Study provides evidence that an AHI ranging from 0.1 to 5 events per hour is enough to increase the risk of developing high blood pressure by 42% [2]. From an AHI of 0.1 to one of 18 events per hour, which cut-off point should be used in FM research? Should it be derived from the emergence of symptoms, from literature reviews, or from hypertension research? …
Literature
1.
go back to reference Togo F, Natelson BH, Cherniack NS, FitzGibbons J, Garcon C, Rapoport DM: Sleep structure and sleepiness in chronic fatigue syndrome with or without coexisting fibromyalgia. Arthritis Res Ther. 2008, 10: R56-10.1186/ar2425.PubMedCentralCrossRefPubMed Togo F, Natelson BH, Cherniack NS, FitzGibbons J, Garcon C, Rapoport DM: Sleep structure and sleepiness in chronic fatigue syndrome with or without coexisting fibromyalgia. Arthritis Res Ther. 2008, 10: R56-10.1186/ar2425.PubMedCentralCrossRefPubMed
2.
go back to reference Peppard PE, Young T, Palta M, Skatrud J: Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med. 2000, 342: 1378-1384. 10.1056/NEJM200005113421901.CrossRefPubMed Peppard PE, Young T, Palta M, Skatrud J: Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med. 2000, 342: 1378-1384. 10.1056/NEJM200005113421901.CrossRefPubMed
3.
go back to reference Germanowicz D, Lumertz MS, Martinez D, Margarites AF: Sleep disordered breathing concomitant with fibromyalgia syndrome. J Bras Pneumol. 2006, 32: 333-338.PubMed Germanowicz D, Lumertz MS, Martinez D, Margarites AF: Sleep disordered breathing concomitant with fibromyalgia syndrome. J Bras Pneumol. 2006, 32: 333-338.PubMed
4.
go back to reference Martinez-Lavin M: Biology and therapy of fibromyalgia: Stress, the stress response system, and fibromyalgia. Arthritis Res Ther. 2007, 9: 216-10.1186/ar2146.PubMedCentralCrossRefPubMed Martinez-Lavin M: Biology and therapy of fibromyalgia: Stress, the stress response system, and fibromyalgia. Arthritis Res Ther. 2007, 9: 216-10.1186/ar2146.PubMedCentralCrossRefPubMed
5.
go back to reference Félix FHC, Fontenele JB: Is fibromyalgia a cardiovascular disease? A comment on Martinez-Lavin's review 'Stress, the stress response system, and fibromyalgia'. Arthritis Res Ther. 2007, 9: 404-10.1186/ar2296.PubMedCentralCrossRefPubMed Félix FHC, Fontenele JB: Is fibromyalgia a cardiovascular disease? A comment on Martinez-Lavin's review 'Stress, the stress response system, and fibromyalgia'. Arthritis Res Ther. 2007, 9: 404-10.1186/ar2296.PubMedCentralCrossRefPubMed
Metadata
Title
How much sleep apnea is too much?
Authors
Denis Martinez
Cristiane Maria Cassol
Laura Rahmeier
Publication date
01-08-2009
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 4/2009
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar2690

Other articles of this Issue 4/2009

Arthritis Research & Therapy 4/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.